Sussex Research Online: No conditions. Results ordered -Date Deposited. http://sro.sussex.ac.uk/ http://sro.sussex.ac.uk/images/sitelogo.png Sussex Research Online: No conditions. Results ordered -Date Deposited. http://sro.sussex.ac.uk/ Fri, 10 Nov 2023 16:22:35 +0000 Fri, 10 Nov 2023 16:22:35 +0000 en Thu, 12 Jan 2023 09:21:00 +0000 KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab http://sro.sussex.ac.uk/id/eprint/110107/ http://sro.sussex.ac.uk/id/eprint/110107/ Schirripa, Marta, Loupakis, Fotios, Cremolini, Chiara, Yang, Dongyun, Labonte, Melissa Janae, Zhang, Wu, Salvatore, Lisa, Wakatsuki, Takeru, El-Khoueiry, Rita, Antoniotti, Carlotta, Aprile, Giuseppe, Maus, Martin Karl Herbert, Lucchesi, Sara, Allegrini, Giacomo, De Vita, Fernando, Zhang, Hua, Giamas, Georgios, Stebbing, Justin, Falcone, Alfredo and Lenz, Heinz-Josef (2012) KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab. Journal of Clinical Oncology, 30 (15). p. 3546. ISSN 0732-183X Wed, 18 May 2022 07:34:59 +0100 Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk http://sro.sussex.ac.uk/id/eprint/105961/ http://sro.sussex.ac.uk/id/eprint/105961/ de Tute, Ruth M, Pawlyn, Charlotte, Cairns, David A, Davies, Faith E, Menzies, Tom, Rawstron, Andy, Jones, John R, Hockaday, Anna, Henderson, Rowena, Cook, Gordon, Drayson, Mark T, Jenner, Matthew W, Kaiser, Martin F, Gregory, Walter M, Morgan, Gareth J, Jackson, Graham H and Owen, Roger G (2022) Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. Journal of Clinical Oncology. pp. 1-12. ISSN 0732-183X Wed, 04 Aug 2021 07:31:24 +0100 Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update http://sro.sussex.ac.uk/id/eprint/100918/ http://sro.sussex.ac.uk/id/eprint/100918/ Burstein, Harold J, Somerfield, Mark R, Barton, Debra L, Dorris, Ali, Fallowfield, Lesley J, Jain, Dharamvir, Johnston, Stephen R D, Korde, Larissa A, Litton, Jennifer K, Macrae, Erin R, Peterson, Lindsay L, Vikas, Praveen, Yung, Rachel L and Rugo, Hope S (2021) Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. Journal of Clinical Oncology. pp. 1-19. ISSN 0732-183X Wed, 28 Mar 2018 16:38:02 +0100 CD49d Is the strongest flow cytometry–based predictor of overall survival in chronic lymphocytic leukemia http://sro.sussex.ac.uk/id/eprint/74715/ http://sro.sussex.ac.uk/id/eprint/74715/ Bulian, Pietro, Shanafelt, Tait D, Fegan, Chris, Zucchetto, Antonella, Cro, Lilla, Nückel, Holger, Baldini, Luca, Kurtova, Antonina V, Ferrajoli, Alessandra, Burger, Jan A., Gaidano, Gianluca, Del Poeta, Giovanni, Pepper, Chris, Rossi, Davide and Gattei, Valter (2014) CD49d Is the strongest flow cytometry–based predictor of overall survival in chronic lymphocytic leukemia. Journal of Clinical Oncology, 32 (9). pp. 897-904. ISSN 0732-183X Tue, 05 Jul 2016 14:10:58 +0100 Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline http://sro.sussex.ac.uk/id/eprint/61896/ http://sro.sussex.ac.uk/id/eprint/61896/ Rugo, Hope S, Rumble, R Bryan, Macrae, Erin, Barton, Debra L, Connolly, Hannah Klein, Dickler, Maura N, Fallowfield, Lesley, Fowble, Barbara, Ingle, James N, Jahanzeb, Mohammad, Johnston, Stephen R D, Korde, Larissa A, Khatcheressian, James L, Mehta, Rita S, Muss, Hyman B and Burstein, Harold J (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology, 34 (25). pp. 3069-3103. ISSN 0732-183X Wed, 20 Jan 2016 12:36:45 +0000 Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice http://sro.sussex.ac.uk/id/eprint/57940/ http://sro.sussex.ac.uk/id/eprint/57940/ Goyal, Amit, Dodwell, David, Reed, Malcolm W and Coleman, Robert E (2014) Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice. Journal of Clinical Oncology, 32 (34). p. 3902. ISSN 0732-183X Thu, 18 Jun 2015 13:26:36 +0100 Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening http://sro.sussex.ac.uk/id/eprint/54598/ http://sro.sussex.ac.uk/id/eprint/54598/ Menon, Usha, Ryan, Andy, Kalsi, Jatinderpal, Gentry-Maharaj, Aleksandra, Dawnay, Anne, Habib, Mariam, Apostolidou, Sophia, Singh, Naveena, Benjamin, Elizabeth, Burnell, Matthew, Davies, Susan, Sharma, Aarti, Gunu, Richard, Godfrey, Keith, Lopes, Alberto, Oram, David, Herod, Jonathan, Williamson, Kevin, Seif, Mourad W, Jenkins, Howard, Mould, Tim, Woolas, Robert, Murdoch, John B, Dobbs, Stephen, Amso, Nazar N, Leeson, Simon, Cruickshank, Derek, Scott, Ian, Fallowfield, Lesley, Widschwendter, Martin, Reynolds, Karina, McGuire, Alistair, Campbell, Stuart, Parmar, Mahesh, Skates, Steven J and Jacobs, Ian (2015) Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening. Journal of Clinical Oncology, 33 (18). pp. 2062-2071. ISSN 0732-183X Mon, 18 Mar 2013 13:43:57 +0000 Prognosis of 368 women with primary breast cancer diagnosed during pregnancy: results from an international collaborative trial http://sro.sussex.ac.uk/id/eprint/43810/ http://sro.sussex.ac.uk/id/eprint/43810/ Loibl, S, Hans, S, vonMinckwitz, G, Botenbal, M, Ring, A, Giermek, J, Fehm, T, Van Calsteren, K, Linn, SC, Schlehe, B, Gziri, MM, Westenend, PJ, Muller, V, Heyns, L, Rack, B, Van Calster, B, Harbeck, N and Lenhard, M (2012) Prognosis of 368 women with primary breast cancer diagnosed during pregnancy: results from an international collaborative trial. Journal of Clinical Oncology, 72 (24 Sup). P6-07. ISSN 0732-183X Wed, 14 Nov 2012 12:31:37 +0000 Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. http://sro.sussex.ac.uk/id/eprint/41955/ http://sro.sussex.ac.uk/id/eprint/41955/ Schmid, Peter, Untch, Michael, Kossé, Valentin, Bondar, Grigorij, Vassiljev, Leonid, Tarutinov, Valerie, Lehmann, Ute, Maubach, Lutz, Meurer, Juergen, Wallwiener, Diethelm and Possinger, Kurt (2007) Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. Journal of Clinical Oncology, 25 (18). pp. 2509-2515. ISSN 1527-7755 Thu, 01 Nov 2012 15:21:20 +0000 Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study http://sro.sussex.ac.uk/id/eprint/41314/ http://sro.sussex.ac.uk/id/eprint/41314/ Blohmer, Jens-Uwe, Paepke, Stefan, Sehouli, Jalid, Boehmer, Dirk, Kolben, Martin, Würschmidt, Florian, Petry, Karl U, Kimmig, Rainer, Elling, Dirk, Thomssen, Christoph, von Minckwitz, Gunter, Möbus, Volker, Hinke, Axel, Kümmel, Sherko, Budach, Volker, Lichtenegger, Werner and Schmid, Peter (2011) Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. Journal of Clinical Oncology, 29 (28). pp. 3791-3797. ISSN 1527-7755 Thu, 01 Nov 2012 15:11:56 +0000 High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials http://sro.sussex.ac.uk/id/eprint/41304/ http://sro.sussex.ac.uk/id/eprint/41304/ Berry, Donald A, Ueno, Naoto T, Johnson, Marcella M, Lei, Xiudong, Caputo, Jean, Smith, Dori A, Yancey, Linda J, Crump, Michael, Stadtmauer, Edward A, Biron, Pierre, Crown, John P, Schmid, Peter, Lotz, Jean-Pierre, Rosti, Giovanni, Bregni, Marco and Demirer, Taner (2011) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. Journal of Clinical Oncology, 29 (24). pp. 3224-3231. ISSN 1527-7755 Tue, 31 Jul 2012 09:50:58 +0100 Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial http://sro.sussex.ac.uk/id/eprint/6999/ http://sro.sussex.ac.uk/id/eprint/6999/ Cella, D and Fallowfield, L (2005) Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial. Journal of Clinical Oncology, 23 (16S). p. 577. ISSN 0732-183X Mon, 30 Apr 2012 09:30:48 +0100 Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. http://sro.sussex.ac.uk/id/eprint/7664/ http://sro.sussex.ac.uk/id/eprint/7664/ Ring, A, Sestak, I, Baum, M, Howell, A, Buzdar, A, Dowsett, M, Forbes, J F and Cuzick, J (2011) Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. Journal of Clinical Oncology, 29 (32). pp. 4266-4272. ISSN 1527-7755 Tue, 24 Apr 2012 10:53:34 +0100 Can communication skills training alter physicians' beliefs and behavior in clinics? http://sro.sussex.ac.uk/id/eprint/7518/ http://sro.sussex.ac.uk/id/eprint/7518/ Jenkins, Valerie and Fallowfield, Lesley (2002) Can communication skills training alter physicians' beliefs and behavior in clinics? Journal of Clinical Oncology, 20 (3). pp. 765-769. ISSN 0277-3732 Wed, 04 Apr 2012 09:22:39 +0100 The influences of co-morbidities and age on risk of death without recurrence: an analysis of the ATAC trial http://sro.sussex.ac.uk/id/eprint/7230/ http://sro.sussex.ac.uk/id/eprint/7230/ Ring, Alistair, Sestak, Ivana, Baum, Michael, Howell, Anthony, Buzdar, Aman, Dowsett, Mitch, Forbes, John F. and Cuzick, Jack (2011) The influences of co-morbidities and age on risk of death without recurrence: an analysis of the ATAC trial. Journal of Clinical Oncology, 29 (32). pp. 4266-4272. ISSN 0732-183X Wed, 09 Nov 2011 10:26:15 +0000 Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials http://sro.sussex.ac.uk/id/eprint/6992/ http://sro.sussex.ac.uk/id/eprint/6992/ Fallowfield, L.J, Fleissig, A., Edwards, R., West, A., Powles, T. J., Howell, A. and Cuzick, J. (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. Journal of Clinical Oncology, 19 (7). pp. 1885-92. ISSN 0732-183X Fri, 26 Aug 2011 14:22:12 +0100 Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial http://sro.sussex.ac.uk/id/eprint/6995/ http://sro.sussex.ac.uk/id/eprint/6995/ Fallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G. and Howell, A. (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of Clinical Oncology, 22 (21). pp. 4261-71. ISSN 0732-183X Tue, 23 Aug 2011 11:06:41 +0100 What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions http://sro.sussex.ac.uk/id/eprint/7302/ http://sro.sussex.ac.uk/id/eprint/7302/ Jenkins, Valerie, Solis-Trapala, Ivonne, Langridge, Carolyn, Catt, Susan, Talbot, Denis C. and Fallowfield, Lesley J (2011) What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. Journal of Clinical Oncology, 29 (1). pp. 61-68. ISSN 0732-183X Tue, 16 Aug 2011 11:26:48 +0100 Chemotherapy for breast cancer during pregnancy: An 18-year experience from five London teaching hospitals http://sro.sussex.ac.uk/id/eprint/7228/ http://sro.sussex.ac.uk/id/eprint/7228/ Ring, Alistair, Smith, I.E., Jones, A., Shannon, C., Galani, E. and Ellis, P.A. (2005) Chemotherapy for breast cancer during pregnancy: An 18-year experience from five London teaching hospitals. Journal of Clinical Oncology, 23 (18). pp. 4192-4197. ISSN 0732-183X Tue, 16 Aug 2011 11:19:00 +0100 Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? http://sro.sussex.ac.uk/id/eprint/7227/ http://sro.sussex.ac.uk/id/eprint/7227/ Ring, Alistair, Webb, A., Ashley, S., Allum, W.H., Ebbs, S., Gui, G., Sacks, N.P., Walsh, G. and Smith, I.E. (2003) Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? Journal of Clinical Oncology, 21 (24). pp. 4540-4545. ISSN 0732-183X Tue, 16 Aug 2011 11:01:07 +0100 A randomized Phase III trial of Sequential Adjuvant Chemo-Radiotherapy with or without Epoetin Alfa in Patients with High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study http://sro.sussex.ac.uk/id/eprint/7224/ http://sro.sussex.ac.uk/id/eprint/7224/ Blohmer, J.U., Paepke, P., Sehouli, J., Boehmer, D., Kolben, M., Würschmidt, F., Petry, K.U., Kimmig, R., Elling, D., Thomssen, C., von Minckwitz, G., Möbus, V., Hinke, A., Kümmel, S., Budach, V., Lichtenegger, W. and Schmid, P. (2011) A randomized Phase III trial of Sequential Adjuvant Chemo-Radiotherapy with or without Epoetin Alfa in Patients with High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study. Journal of Clinical Oncology, 29 (28). pp. 3791-3797. ISSN 0732-183X Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer http://sro.sussex.ac.uk/id/eprint/681/ http://sro.sussex.ac.uk/id/eprint/681/ Fallowfield, Lesley J., Bliss, Judith M., Porter, Lucy S., Price, Miranda H., Snowdon, Claire F., Jones, Stephen E., Coombes, R. Charles and Hall, Emma (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology, 24 (6). pp. 910-917. ISSN 0732-183X